Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Wednesday's Analyst Blog:

Glaxo's Avandia Issue Priced-In

Sales of Avandia have been significantly negatively impacted due to safety concerns, but it appears they have recently stabilized. We believe that sales are now at, or very near, their bottom. While sales of Avandia have been cut in half from their peak level reached in 2006, it remains a very important product to GlaxoSmithKline plc (GSK), and stabilizing sales would be very good news.

Other than the Avandia issue, Glaxo still has to deal with generic erosion of a number of drugs, including Coreg IR, Flonase, Wellbutrin XR, Lamictal, Requip, Valtrex and Imitrex. On the positive front, we continue to be impressed by the vaccine franchise and look forward to the contribution from Rotarix, Promacta and Synflorix. And although we were disappointed by the recent delay with Cervarix, we remain confident that it will eventually be a big growth driver for the vaccine business. Advair sales should see some incremental revenue growth from the recent launch in Japan.

General Growth Rallies Again

Shares of General Growth Properties (GGP) were up 8% yesterday, after jumping 35% Monday, despite two down days for the sector. Volumes have spiked as well, 46 million shares were traded yesterday and 25 million today, vs. three months daily average of about 8 million shares.

GGP issued a statement after an inquiry from the NYSE which stated that the company is "unaware of any corporate developments that might explain the unusual market activity." GGP has been in continuous negotiations with bond holders and lenders to try to extend debt maturities and modify payments. Deadlines continue to be extended as not all bondholders have agreed to the company's proposed modifications.

Agria Sales to Fall

Agria Corp's (GRO) financial performance through the first nine months has been hampered by significantly lower seed prices and a disruption in production of sheep-breeding products. We would not categorize the cause of either to be inherent fundamental issues that would be expected to affect sales for the long-term.

Sheep-breeding revenue should continue to rebound in the fourth quarter and into 2009. While corn seed prices will likely remain depressed until the excess inventory in the market is consumed, we do not expect this to be a protracted event.

Regis Corp. Not Cutting It

Sell-rated Regis Corporation (RGS), the largest beauty salon company in the country, announced this morning that third quarter revenues declined 2.5% versus the prior year. Excluding the deconsolidation of its European salon operations, revenues would have been down 1.7%.

More importantly, in our opinion, is the fact that same-store-sales decreased 4.5% year-over-year.

With more than 12,800 system-wide locations throughout the world, Regis is substantially larger than peers such as Ulta Salon, Cosmetics & Fragrance, Inc. (ULTA). The company has interests in a wide range of salon concepts, including higher-end salons such as the Regis brand, which has an average ticket of $37, and lower-cost brands such as MasterCuts and Supercuts, which have average tickets of $17 and $14, respectively.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com

The deal allows Martek to continue its international expansion into Mexico, Europe, and China. Martek's proprietary DHA and ARA blend is used in approximately 95% of infant formulas sold in the U.S.

On Sep 4 Martek announced third-quarter earnings that included earnings per share of 28 cents. This market the fourth surprise in the past 4 quarters, as analysts were only expecting 24 cents. Revenues rose 14% year-over-year to $88.4 million.

Martek also raised full-year guidance during the announcement. The company expects earnings per share to be between $1.06 and $1.09, 65% higher that 2007.

The company was featured earlier this year as a Zacks Rank Buy.

Read the March 11th analysis.

Last Week's Aggressive Growth Zacks Rank Buy Stocks

Ulta Salon, Cosmetics & Fragrance, Inc. (ULTA) continues to aggressively expand its footprint across the U.S. The beauty retailer and salon is also coming of off its third earnings surprise and is priced at a reasonable PEG ratio of 0.58. Read Full Article.

Perrigo Company (PRGO) has acquired 2 more laboratories this quarter in a focused effort on growth in existing markets. The company is also coming off of a record quarterly earnings report. Read Full Article.

Revlon, Inc. (REV) is paying down debt and focusing on its core business. The company has also seen an increase in sales despite a tough economy. Read Full Article.

Zhongpin Inc. (HOGS) just raised earnings guidance and it trading at a bargain PEG ratio of just 0.26. The company hopes to build off of a second quarter as one of its newest plants is already contributing to revenue. Read Full Article.
"MATK" Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research